Michael Risbano
University of Pittsburgh
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Risbano as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:30 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07223528 · TEPH: Telaglenastat Efficacy in Pulmonary HypertensionChan, Stephen, MD, PhD · not yet recruiting · Pulmonary Hypertension · principal investigator
- N/ANCT03905083 · miRNA and Myokines in Patients With PAHUniversity of Pittsburgh · withdrawn · Pulmonary Arterial Hypertension · principal investigator
- Ph2NCT03629340 · Metformin for Pulmonary Hypertension HFpEFUniversity of California, San Francisco · completed · Pulmonary Hypertension, Heart Failure · principal investigator
- Ph2NCT03015402 · Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection FractionUniversity of Pittsburgh · completed · Pulmonary Hypertension Secondary, Heart Failure · principal investigator
- N/ANCT01581086 · Vascular Subphenotypes of Lung Disease in HIV & COPDUniversity of Pittsburgh · completed · Pulmonary Artery Hypertension · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Pathogenic Mechanism and Therapeutic Approaches for Exercise Intolerance in Post-Acute Sequelae of COVID-19R01HL176493 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2025 to 2026 · $618,218 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection FractionR01AG058659 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARC A SIMON · fiscal years 2018 to 2022Named on NCT03629340
- Therapeutic Targeting of Vascular Subphenotypes of Lung DiseaseP01HL103455 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Alison Morris · fiscal years 2011 to 2020Named on NCT03015402
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:30 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results.Eur Respir J · 202467 citationsRCR 12.2
- Effects of Aged Stored Autologous Red Blood Cells on Human Endothelial Function.Am J Respir Crit Care Med · 201558 citationsRCR 2.6